Trimodulin - Biotest

Drug Profile

Trimodulin - Biotest

Alternative Names: BT 588; BT086; IgM concentrate - Biotest

Latest Information Update: 03 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biotest AG
  • Class Antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Community-acquired pneumonia

Most Recent Events

  • 03 Nov 2017 Efficacy data from a phase II trial in severe community-acquired pneumonia released by Biotest (Biotest pipeline, November 2017)
  • 03 Nov 2017 Biotest plans a phase III trial for severe community-acquired pneumonia (Biotest pipeline, November 2017)
  • 01 Apr 2015 Biotest AG completes a phase) II trial in Community acquired pneumonia (Adjunctive therapy) in United Kingdom, Belgium, Spain and Germany (NCT01420744)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top